Navigation Links
First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Date:9/17/2007

for postmenopausal osteoporosis was based on the results of the Pivotal Fracture Trial, which involved more than 7,700 women. In the study, published in The New England Journal of Medicine in May 2007, Reclast was shown to increase bone strength and reduce fractures in areas of the body typically affected by osteoporosis, including the hip, spine and non- spine (i.e., hip, wrist, arm, leg, rib). Reclast is the only treatment approved to reduce the risk of fractures across all of these key sites. The study showed Reclast reduced the risk of spine fractures by 70% and hip fractures by 41% (4).

Reclast belongs to a class of drugs called bisphosphonates, which are used to treat osteoporosis, the most common metabolic bone disease affecting more than 10 million people in the US (2). Unlike oral bisphosphonate treatments, where patients take daily, weekly or monthly doses of medication, Reclast is given as a once-yearly infusion.

In July 2007, the Committee for Medicinal Products for Human Use (CHMP) also issued a positive opinion recommending approval in the European Union, under the brand name Aclasta(R). The European Commission generally follows the CHMP's recommendations and is expected to issue a final decision within three months.

Reclast is approved in more than 60 countries, including the US, Canada and the EU for the treatment of Paget's disease of the bone, the second most common metabolic bone disorder. Additional studies are ongoing to examine the use of Reclast to treat corticosteroid-induced osteoporosis, male osteoporosis and bone loss in postmenopausal women with osteopenia.

The active ingredient in Reclast is zoledronic acid, which is also available in a different dosage under the brand name Zometa(R) (zoledronic acid 4 mg) Injection for use in certain oncology indications.

Reclast is contraindicated in patients with hypocalcemia (low blood calcium) and those who are allergic to zoledronic acid. Reclast contains the same acti
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... YORK , May 22, 2013  The Lupus ... conference devoted to advancing new treatments for lupus nephritis, ... 60 percent of patients. The conference launched a new ... the Lupus Nephritis Trials Network (LNTN). More ... and the kidney came together to focus on two ...
(Date:5/22/2013)... , May 22, 2013 The new ... safe as the previous version used prior to 2010, ... Kaiser Permanente study published today in Vaccine. ... use beginning in 2010 after a series of trials. ... broader range of pneumococcal types than the previously used ...
(Date:5/22/2013)... , May 22, 2013  Healthcare ... enterprise content management (ECM) solution, ... Hospital Information System .  These organizations identified ... system and will use OnBase to optimize ... initiatives.   (Logo:  http://photos.prnewswire.com/prnh/20090130/65710LOGO ...
Breaking Medicine Technology:Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 2Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 3
... Colorado Cancer,Research Program (CCRP) invites golfers to participate in its ... at the Valley Country Club,14601 Country Club Drive, Aurora. The ... been the home to major events such as the,Colorado Women,s ... professional,golfers have been inducted into the Colorado Hall of Fame., ...
... TAMPA, Fla., April 27 Calvin A. ... from his 60-patient,retrospective case control study that ... Xibrom(TM) (bromfenac 0.09mg ophthalmic solution) in Lucentis(R),(ranibizumab) ... degeneration (AMD) in an oral poster presentation ...
Cached Medicine Technology:Colorado Cancer Research Program Will Host Golf Event to 'Drive' the Message that Clinical Trials Play a Vital Role in the Quest to Find a Cure for Cancer 2Colorado Cancer Research Program Will Host Golf Event to 'Drive' the Message that Clinical Trials Play a Vital Role in the Quest to Find a Cure for Cancer 3Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 3Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 4
(Date:5/22/2013)... The Muscular Dystrophy Association scored a huge ... annual Charlotte Muscle Team event held May 21 by ... with muscle disease. , "The Charlotte community really ... families,” said MDA Divisional Director Theresa Miller. “From the ... "Buddy" to make their night extra special, to the ...
(Date:5/22/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) -- ... more likely to attempt suicide, whether or not they ... to a new study. "Clinicians who are seeing ... are at increased risk of suicide," said study co-author ... Treatment Resource and Evaluation Center in Ann Arbor, Mich. ...
(Date:5/22/2013)... Rapids, IA (PRWEB) May 22, 2013 ... theatre piece Handicap This! The performance promotes awareness ... their dreams. The Handicap This! performance will be held ... Mar High School auditorium. Tickets for Handicap This! ... Handicap This! helps audiences measure the level to which ...
(Date:5/22/2013)... SAN FRANCISCO Researchers in genomic health disparities from ... the Stanford University School of Medicine have teamed up ... Conference to Eliminate Health Disparities in Genomic Medicine." ... role of nonprofits, business and government to reduce these ... of the United States, individuals within underserved groups continue ...
(Date:5/22/2013)... New York (PRWEB) May 22, 2013 ... has established the Westchester Lung Nodule Center for ... or receive lung cancer care. Lung cancer is the deadliest ... year, more people in the U.S. die from lung cancer ... As with all cancers, early detection increases survival rates. ...
Breaking Medicine News(10 mins):Health News:Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 3Health News:Handicap This! Comes to Marion, Iowa 2Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3
... eCare, an initiative that employs information,and advanced technologies ... care, WILLIAMSBURG, Va., June 18 The ... and Mary proudly announces that,Professor Dorothea La "Chon" ... awards available to a faculty member in a ...
... source; New York City links 7 infections to salmonella ... number of people known to have fallen ill after ... 30 states plus the District of Columbia, U.S. health ... not due to new infections but mainly because some ...
... Corporation,(Nasdaq: AIRM ), the largest air medical ... Executive Officer Aaron Todd and Chief,Financial Officer Trent ... Conference in New York City on Tuesday, June ... can listen to the presentation via a live ...
... strike small percentage of patients , , WEDNESDAY, June 18 ... new side effect associated with the cancer drug Gleevec ... leukemia and gastrointestinal stromal tumors. , In a letter ... New England Journal of Medicine , the doctors describe ...
... seizures, SPOKANE, Wash., June 18 The Epilepsy,Foundation ... this Saturday, June 21 in Spokane at Riverfront Park ... from 9:30 am - 12:30 pm., "Everyone is ... with epilepsy," said Ryan Oelrich, Program Manager. "We are ...
... Berkeley The newly sequenced genome of a dainty, quill-like ... that vertebrates evolved over the past 550 million years through ... ,The late geneticist Susumu Ohno argued in 1970 ... evolution of higher organisms, and Ohno,s theory was the basis ...
Cached Medicine News:Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 2Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 3Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 4Health News:Professor Chon Abraham of the Mason School of Business at The College of William & Mary named Fulbright Scholar 5Health News:Tainted Tomato Cases Jump to 383 People in 30 states, D.C. 2Health News:Tainted Tomato Cases Jump to 383 People in 30 states, D.C. 3Health News:Cancer Drug Gleevec Linked to Muscle Damage 2Health News:Genome sequence of lancelet shows how genes quadrupled during vertebrate evolution 2Health News:Genome sequence of lancelet shows how genes quadrupled during vertebrate evolution 3Health News:Genome sequence of lancelet shows how genes quadrupled during vertebrate evolution 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: